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Aberrant Wnt1/-Catenin Expression is an Independent
Poor Prognostic Marker of Non-small Cell Lung Cancer
After Surgery
Xianhua Xu, MD,* Ping-Li Sun, MD,*† Jun-Zhe Li, MD,‡ Sanghoon Jheon, MD, PhD,†
Choon-Taek Lee, MD, PhD,§ and Jin-Haeng Chung, MD, PhD*
Introduction: The Wnt signaling pathway plays a major role in
cancer development and progression. As a novel anticancer drug can
be developed using inhibitors of this pathway, we investigated the
clinical significance of the Wnt signaling pathway molecules in
non-small cell lung cancer (NSCLC).
Methods: Immunohistochemical analysis of a tissue microarray
with 262 resected NSCLC specimens was performed to study the
expression and subcellular localization of Wnt1 in relation to down-
stream molecules, including GSK-3, -catenin, c-Myc, cyclin D1,
and p53. These results were correlated with other clinicopathologic
features.
Results: Cytoplasmic Wnt1 overexpression was detected in 36.6%
(96 of 262) NSCLCs, and aberrant -catenin staining was identified
in 76% (189 of 262) of NSCLCs. There were significant associations
between Wnt1 expression and altered expression of -catenin (p 
0.034), overexpression of c-Myc (p  0.001), or overexpression of
cyclin D1 (p  0.018). While there was no significant association
between Wnt1 or -catenin and stage, the 5-year survival was
significantly lower in patients with Wnt1- and -catenin-positive
NSCLCs than negative NSCLCs (p  0.05, respectively). In mul-
tivariate analysis, stage and Wnt1/-catenin expression were
independent prognostic factors of overall survival (p  0.05).
Conclusion: These findings show that Wnt1 expression may be
one of the possible mechanisms of the activation of the canonical
Wnt/-catenin signaling pathway in NSCLC, and Wnt1 and
altered -catenin expression are poor prognostic markers, inde-
pendent of stage.
Key Words: Lung cancer, Prognosis, Wnt signaling pathway,
Immunohistochemistry.
(J Thorac Oncol. 2011;6: 716–724)
Lung cancer is a highly aggressive and challenging cancerthat now represents the leading cause of cancer deaths
throughout the world.1 Despite progress in the multimodality
treatment of lung cancer in the past several decades, the
5-year survival rate for lung cancer remains poor. Surgery,
chemotherapy, and radiation have failed to yield satisfactory
results in advanced disease.2 Further elucidation of the mo-
lecular mechanism underlying lung cancer is essential for the
development of new effective therapeutic agents. The molec-
ular pathogenesis of lung cancer includes alteration of ex-
pression and function of multiple genes including dominant
oncogenes and recessive oncogenes/tumor-suppressor genes,
alterations in growth-regulatory signaling pathways, and ab-
normalities in other pathways. Among the many molecules
associated with tumorigenesis, the Wingless-type (Wnt) fam-
ily genes are frequently upregulated in different human can-
cers, including non-small cell lung cancer (NSCLC).3,4
The Wnt gene family encodes the multifunctional
signaling glycoproteins that are involved in the regulation
of a wide variety of normal and pathological processes,
including embryogenesis, differentiation, and tumorigene-
sis. Wnt signaling is transduced through -catenin, which
is regulated by the adenomatous polyposis coli (APC)/
Axin/glycogen synthase kinase (GSK)-3 complex.5,6 In
the absence of Wnt signal (off-state), -catenin, an integral
cell-cell adhesion adaptor protein as well as transcriptional
coregulator, is targeted for degradation by the APC/Axin/
GSK-3 complex. In the presence of Wnt stimulation
(on-state), Drosophila dishevelled (Dvl) is activated,
seemingly at least in part by phosphorylation, which in
turn recruits GSK-3 away from the degradation complex.
This allows stabilization of -catenin, resulting in the
accumulation of free cytosolic -catenin. The elevated
-catenin can translocate to the nucleus where it forms a
complex with T-cell factor/lymphoid enhancer binding
factor to stimulate the expression of Wnt target molecules,
such as cyclin D1, c-Myc, peroxisome proliferator-acti-
vated receptor delta (PPAR-), and matrix metalloproteinase
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7 (MMP7).7–10 Increasing evidence indicates that aberrant acti-
vation of the Wnt signaling pathway is associated with
tumor development and/or progression, suggesting that
Wnt signaling functions in oncogenesis, possibly through
antiapoptotic mechanisms.8,11,12 Therefore, inhibition of
Wnt signaling has become an attractive strategy for cancer
therapeutics.13,14 Inhibitors of Wnt/-catenin signaling are
under consideration or development, initially for treatment
of cancers—a promising avenue given that Wnt/-catenin
signaling seems to be involved in cancer progression.15–17
However, it has been known that the Wnt signaling path-
way activation mechanism in lung cancer is different from
that in colorectal cancer.18 In particular, mutations of APC
or -catenin are rarely found in lung cancer, and the Wnt
pathway activation may occur upstream of -catenin.18
It is important to detect specific target molecules of the
Wnt pathway as well as to identify and select the patients who
would benefit from Wnt pathway inhibitors. It remains to be
seen whether or not the inhibitors of specific pathway can be
put into clinical practice, and detailed appraisals of biomarker
expression in the tumor cells should be preceded. To evaluate
the clinical significance of Wnt/-catenin pathway proteins,
we investigated the intratumoral expression of Wnt1 in rela-
tion to downstream molecules, including -catenin, GSK-3,
c-Myc, cyclin D1, and p53 in NSCLC.
PATIENTS AND METHODS
Clinical Data Acquisition
From May 2003 to December 2006, 262 consecutive
lung cancer patients who underwent surgical resection in our
institution were compiled. The tumors consisted of 165
(63.0%) adenocarcinomas (ADCs) and 97 (37.0%) squamous
cell carcinomas (SCCs). The patients given diagnoses other
than ADC or SCC were excluded due to their small number.
None of the patients had received neoadjuvant chemotherapy
or irradiation preoperatively.
Clinical and pathological data were retrieved from the
medical records, including follow-up data as of December
2009. This study was approved by Institutional Review
Board.
Tissue Microarray
Representative core tissue sections (2 mm in diameter)
were taken from paraffin blocks and arranged in new tissue
microarray (TMA) blocks using a trephine apparatus (Super-
biochips Laboratories, Seoul, Korea). In cases with a variety
of histologic features, the most representative area was se-
lected for TMA construction. Six cores were sampled and
included in the TMA block from each patient.
TABLE 1. Pathological Stage of NSCLCs
p Stage n (%)
Ia 57 (21.8%)
Ib 49 (18.7%)
IIa 49 (18.7%)
IIb 25 (9.5%)
IIIa 64 (24.4%)
IIIb 6 (2.3%)
IV 12 (4.6%)
p stage, pathological stage.
TABLE 2. Clinicopathologic Characteristics According to
the Histologic Subtype
Characteristics
Total
n (%)
ADC
n (%)
SCC
n (%) p
Total 262 (100.0) 165 (63.0) 97 (37.0)
Sex
Male 184 (70.2) 93 (56.4) 91 (93.8) 0.001
Female 78 (29.8) 72 (43.6) 6 (6.2)
Age (yr)
65 147 (56.1) 102 (61.8) 45 (46.4) 0.020
65 115 (43.9) 63 (38.2) 52 (53.6)
Smoking
Nonsmoker 94 (35.9) 89 (53.9) 5 (5.2) 0.001
Smoker 168 (64.1) 76 (46.1) 92 (94.8)
Size
3 cm 146 (55.7) 101 (61.2) 45 (46.4) 0.021
3 cm 116 (44.3) 64 (38.8) 52 (53.6)
Pleural invasion
Absent 156 (59.5) 90 (54.5) 66 (68.0) 0.037
Present 106 (40.5) 75 (45.5) 31 (32.0)
Vascular invasion
Absent 222 (84.7) 148 (89.7) 74 (76.3) 0.004
Present 40 (15.3) 17 (10.3) 23 (23.7)
Tumor status
T1 81 (30.9) 57 (34.5) 24 (24.7) NS
T2 125 (47.7) 77 (46.7) 48 (49.5)
T3 41 (15.6) 20 (12.1) 21 (21.6)
T4 15 (5.7) 11 (6.7) 4 (4.1)
Nodal status
N0 143 (54.6) 93 (56.4) 50 (51.5) NS
N1 60 (22.9) 27 (16.4) 33 (34.0)
N2 58 (22.1) 45 (27.3) 13 (13.4)
N3 1 (0.4) 0 (0.0) 1 (1.0)
p stage
I 106 (40.5) 78 (47.3) 28 (28.9) NS
II 74 (28.2) 28 (17.0) 46 (47.4)
III 70 (26.7) 52 (31.5) 18 (18.6)
IV 12 (4.6) 7 (4.2) 5 (5.2)
ECOG PS
0 170 (64.9) 121 (73.3) 49 (50.5) 0.001
1, 2 92 (35.1) 44 (26.7) 48 (49.5)
Recur
Absent 137 (52.3) 88 (53.3) 49 (50.5) NS
Present 125 (47.7) 77 (46.7) 46 (47.4)
Survival
Alive 194 (74.0) 127 (77.0) 67 (69.1) 0.010
Deceased 68 (26.0) 37 (22.4) 23 (23.7)
ADC, adenocarcinoma; SCC, squamous cell carcinoma; NS, not significant; p
stage, pathological stage; ECOG PS: Eastern Cooperative Oncology Group performance
status.
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Immunohistochemical Assays
We deparaffinized 4-m sections from the TMA blocks
in xylene and rehydrated them in graded ethanol. The suc-
ceeding steps were performed automatically at 37°C using the
BenchMark XT Slide Staining System Specifications (Ven-
tana Medical Systems, Tucson, AZ). Endogenous peroxi-
dases were quenched with 1% H2O2 for 4 minutes. The
sections were incubated with the rabbit polyclonal antibody
for Wnt1 (H-89, Santa Cruz Biotechnology, Santa Cruz, CA,
dilution 1:100), the rabbit polyclonal antibody for GSK-3
(H-76, Santa Cruz, dilution 1:100), the mouse monoclonal
antibody for -catenin (5H10, Zymed Laboratories, San
Francisco, CA, dilution 1:1000), the mouse monoclonal an-
tibody for c-Myc (9E11, Santa Cruz, dilution 1:5000), the
rabbit monoclonal antibody for cyclin D1 (SP4, Thermo
Fisher Scientific, Waltham, MA, dilution 1:100), and the
mouse monoclonal antibody for p53 (DO-7, Dako, Glostrup,
Denmark, dilution 1:1000). The secondary biotinylated anti-
body was incubated for 8 minutes. The slides were stained
using a diaminobenzidine detection kit and counterstained
with hematoxylin.
Specimens were evaluated under light microscopy by
two independent pathologists (X.X. and J.H.C.) and scored
based on a semiquantitative approach of that percentage of
positive tumor cells (0–100%), multiplied by staining inten-
sity (0 negative, 1 weak, 2 moderate, 3 strong). For
the expression of Wnt1, GSK-3, c-Myc, and cyclin D1, a
total score range of 0 to 300 was generated for each sample,
where 0 to 100 was classified as negative and 101 to 300 was
classified as positive. Regarding the -catenin expression, we
used the classification of staining patterns as follows: (1) a
membranous pattern, if immunoreactivity was present solely
at the cell membranes; (2) a membranous-cytoplasmic pat-
tern, if immunoreactivity was also present in the cytoplasm;
(3) a cytoplasmic pattern, if immunoreactivity was chiefly
present in the cytoplasm and in less than 20% of the nuclei;
FIGURE 1. Immunohistochemical staining of Wnt pathway proteins in non-small cell lung cancer. Cytoplasmic expression of
Wnt1 (A, B), GSK-3b (C), normal membranous pattern of -catenin (D), membranous-cytoplasmic pattern of -catenin (E, F),
cytoplasmic pattern of -catenin (G), cytoplasmic-nuclear pattern of -catenin (H, I), positive expression of c-Myc (J), cyclin
D1 (K), and p53 (L).
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and (4) a cytoplasmic-nuclear pattern, if immunoreactivity
was present in the cytoplasm and concomitantly in more than
20% of the nuclei.19 Strongly positive staining specimens of
the cytoplasmic-nuclear, membranous-cytoplasmic, and cy-
toplasmic patterns (10%) were taken as positive.20 Also, the
specimens of membranous pattern (70%) were estimated as
the reduced -catenin expression.21
Statistical Analysis
The analyses were performed using the software pack-
age Statistical Package for Social Sciences, version 17.0, for
Windows (SPSS, Chicago, IL). The 2 test was used to
evaluate the association between Wnt signaling pathway
proteins and each of the clinicopathologic characteristics. p
values less than 0.05 were considered to medical statistically
significant difference.
Kaplan-Meier analysis was performed for survival
curves, and statistical significance was assessed using the
log-rank test. Overall survival was defined as the time from
the treatment initiation (resection) to the date of death. To
evaluate whether a biomarker is an independent prognostic
factor of overall survival, multivariate analysis using the Cox
proportional hazard regression model was performed. All p
values were based on the two-sided statistical analysis, and p
value less than 0.05 was considered to indicate statistical
significance.
RESULTS
Patient Characteristics
Patients consisted of 184 (70.2%) male and 78 (29.8%)
female with a median age of 64 years (range, 20–81), with 94
(35.9%) nonsmokers and 168 (64.1%) smokers. The hema-
toxylin and eosin-stained slides were reviewed to confirm the
original diagnosis by two pathologists (X.X. and J.H.C.)
independently, which was based on the World Health Orga-
nization criteria.22 The 262 patients were classified using the
7th Edition of the International Union Against Cancer and
American Joint Committee on Cancer TNM classification of
Malignant Tumors from the International Association for the
Study of Lung Cancer23 as follows: pathological stage (p
stage) I, 106 (40.5%) patients; p stage II, 74 (28.2%) patients;
p stage III, 70 (26.7%) patients; p stage IV, 12 (4.6%) patients
(Table 1). The male to female ratios were 1.3:1 and 15.2:1 in
ADC and SCC patients (p  0.001). The patients with ADC
were younger than the patients with SCC (p 0.020), and the
tumor size of ADC was smaller than that of SCC (p 0.021).
Among the SCC patients, 94.8% had a history of smoking,
but only 46.1% of the ADC patients were smokers (p 
0.01). There were statistical differences in pleural invasion,
vascular invasion, Eastern Cooperative Oncology Group per-
formance status (ECOG PS), and survival between the two
histological subtypes (p  0.05, respectively). The detailed
clinicopathologic characteristics in this study are summarized
in Table 2.
Wnt Pathway Proteins Expression in NSCLCs
The Wnt1 expression appeared in the form of a cyto-
plasmic staining pattern (Figure 1A, B). The Wnt1 expressionTA
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was negative in the non-neoplastic type I or type II pneumo-
cytes, bronchiolar epithelial cells, mesenchymal cells, and
inflammatory cells. Regarding the intratumoral Wnt1 expres-
sion, 96 (36.6%) carcinomas were positive. The expression of
Wnt1 was significantly higher in the tumors in nonsmokers
(p  0.012), with ADC histology (p  0.001), absence of
lymphatic invasion (p  0.04), and necrosis less than 10%
(p  0.031) (Table 3). No significant differences were ob-
served according to the sex, age, tumor size, pleura invasion,
vascular invasion, perineural invasion, tumor, node, metasta-
sis (TNM) stage, ECOG PS, and recurrence.
The GSK-3 expression appeared in the form of a
cytoplasmic staining pattern (Figure 1C). Regarding the in-
tratumoral GSK-3 expression, 70 (26.7%) carcinomas were
positive. The GSK-3 status was significantly higher in male
(p  0.021), old age (p  0.049), smokers (p  0.020), SCC
histology (p  0.001), and necrosis 10% (p  0.028)
(Table 3). While the expression pattern of GSK-3 appeared
quite different from Wnt1, there was no significant associa-
tion between Wnt1 and GSK-3 (Table 4).
The -catenin expression exhibited four staining pat-
terns (Figures 1D–I). The -catenin expression is localized to
the membrane in normal epithelium, but reduced expression
in membrane, expression in the cytoplasm, and/or nuclear
translocation could be considered to be an indication of its
aberrant expression. The altered -catenin expression was
associated with SCC histology (p  0.036) and presence of
vascular invasion (p  0.008) (Table 3). Among 96 Wnt1-
positive tumors, 81 carcinomas were -catenin positive and
15 were negative. The percentage of -catenin-positive tumor
was significantly higher in Wnt1-positive tumors than in
Wnt1-negative tumors (p  0.034, Table 4).
FIGURE 2. Kaplan-Meier univariate analysis of overall survival curves in 262 non-small cell lung cancer patients with the prognos-
tic parameters including tumor status (A), nodal status (B), p stage (C), pleura invasion (D), vascular invasion (E), lymphatic invasion
(F), perineural invasion (G), necrosis (H), and Eastern Cooperative Oncology Group performance status (ECOG PS) (I).
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Regarding the intratumoral c-Myc expression, 196
(74.8%) carcinomas were positive (Figure 1J). The c-Myc
overexpression was significantly more frequent in female
(p  0.003), nonsmokers (p  0.002), ADC histology (p 
0.01), and necrosis less than 10% (p  0.004) (Table 3). The
percentage of c-Myc-positive tumor was significantly higher
in Wnt1-positive tumors than in Wnt1-negative tumors (p 
0.001, Table 4).
The cyclin D1 expression was localized to the nucleus
(Figure 1K). Regarding the intratumoral cyclin D1 expres-
sion, 103 (39.3%) carcinomas were positive. Cyclin D1 status
was higher in nonsmokers (p  0.001) and ADC patients
(p  0.001) (Table 3). The percentage of cyclin D1-positive
tumor cells was higher and significantly correlated with the
percentage of Wnt1-positive (p  0.018) and c-Myc-positive
tumor cells (p  0.009, Table 4).
p53 Overexpression in Relation to the Wnt
Pathway Proteins Expression
Regarding intratumoral p53 expression, 120 (45.8%)
carcinomas were positive (Figure 1L). The overexpression of
p53 protein was significantly related with male gender (p 
0.004), smoker (p  0.001), SCC histology (p  0.001), and
lymphatic invasion (p  0.035, Table 3). The percentage of
p53-positive tumor cells was significantly higher in GSK-3-
positive tumors than negative tumors, while the percentage
was significantly lower in c-Myc-positive tumors than in
negative tumors (p  0.01, respectively). However, the per-
centage of p53-positive tumor cells was not statistically
related with the percentage of Wnt1-positive tumor cells
(Table 4).
Overall Survival Analysis
At the time of analysis, the number of cancer-specific
deaths was 78 cases (29.8%). On univariate survival anal-
ysis, the conventional prognostic parameters, including
tumor status, nodal status, p stage, pleura invasion, vascu-
lar invasion, lymphatic invasion, perineural invasion, ne-
crosis, and ECOG PS, reached significance for overall
survival (Figure 2). The Wnt1-positive patients had a
significantly shorter survival than Wnt1-negative patients,
as well as -catenin (p  0.05, respectively). The patients
with Wnt1/-catenin NSCLC showed inferior survival
compared with Wnt1/-catenin, Wnt1/-catenin,
and Wnt1/-catenin patients (p  0.031; Figure 3).
The overall survival was inferior in p53-positive tumors
than negative tumors (p  0.005; Figure 3). Multivariate
analysis proved that Wnt1 high expression or -catenin
alteration were independent prognostic factors of overall
survival adjusted by stage, pleural invasion, lymphatic
invasion, and ECOG PS. The Wnt1/-catenin expres-
sion was also an independent factor adjusted by stage,
pleural invasion, lymphatic invasion, ECOG PS or stage,
age, gender, histology, and p53 (p  0.05, respectively;
Table 5).
FIGURE 3. Wnt1-positive non-small cell lung cancers (NSCLCs) showed significantly shorter survival than Wnt1-negative
NSCLCs (A). NSCLCs with -catenin expression showed significantly shorter survival than -catenin-negative NSCLCs (B). The
overall survival was shorter in p53-positive tumors than p53-negative tumors (C). Regarding the two variables, Wnt1 and
-catenin, the overall survival is significantly lower in patients with Wnt1/-catenin than in patients with Wnt1/-
catenin, Wnt1/-catenin, and Wnt1/-catenin NSCLCs (D, E).
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DISCUSSION
The results of the current study demonstrated that Wnt1
expression correlated with Wnt target proteins, including
-catenin, c-Myc and Cyclin D1, which suggested that Wnt1
is an important member stimulating the Wnt/-catenin sig-
naling pathway. As a result, high expression of Wnt1 was
associated with poor prognosis in NSCLC patients after
surgery. Our results corresponded well with a previous study
by Huang et al.,19 which demonstrated that elevated Wnt1
expression was a significant poor prognostic factor in
NSCLC. However, there were some different aspects com-
pared with their study. This study showed higher expres-
sion of Wnt1 in the ADC histology than SCC and the
clinical significance of -catenin, a pivotal target molecule
of Wnt pathway. Although Huang et al. showed significant
correlation between Wnt1 and -catenin expression, they
did not mention the prognostic value of -catenin in
relation to Wnt1.
The aberrant expression of -catenin was higher in
Wnt1-positive NSCLCs than in Wnt1-negative NSCLCs, and
patients with aberrant -catenin expression had shorter sur-
vival in this study. The correlation of -catenin expression
and cellular localization with the prognosis has been de-
scribed previously. Strong nuclear or cytoplasmic -catenin
staining in colorectal cancer correlates with more invasive
tumor growth, a higher susceptibility to disease recurrence
after surgery, and a lower survival rate.24–26 In esophageal
carcinoma, loss of proteins of the E-caderin/-catenin adhe-
sive complex correlated with poor prognosis.27,28 On the
contrary, analysis of hepatocellular carcinomas revealed that
mutation and nuclear staining of -catenin correlated with
less aggressive tumor growth and better survival rates.29,30
These contradictory results are presumed as follows. First, no
standard or universally accepted criteria to evaluate -catenin
expression by immunohistochemistry might generate differ-
ent results. Second, different activation mechanism of the
Wnt signaling pathway in each organ might be present.
Therefore, detailed immunohistochemical assessment of
-catenin expression and standardization is recommended.
However, because there is a subgroup of patients who
had alteration of -catenin but negative Wnt1, -catenin may
be activated through other pathways besides Wnt1, as
-catenin is involved not only in the Wnt pathway but also in
the cadherin cell adhesion system. -catenin plays a dual role
in cells as a major structural component of cell-cell adherence
junctions and as a pivotal signaling molecule in the Wnt
pathway, transmitting transcriptional cues into the nucleus.
Also, the Wnt gene family encodes at least 19 secreted factors
involved in cell growth, differentiation, embryogenesis, and
oncogenesis that another Wnt gene besides Wnt1 may cause
the alteration of -catenin.
A novel finding of our study is that the patients with
double-positive Wnt1/-catenin NSCLC showed signifi-
cantly shorter survival than other groups. We also found that
high expression of Wnt1, alteration of -catenin, and double-
positive Wnt1/-catenin were independent poor prognostic
factors in NSCLC regardless of TNM stage.
GSK-3 is an essential component of the Wnt signaling
pathway and plays important roles in regulating cell prolif-
eration, differentiation, and apoptosis.31 However, GSK-3
expression showed no significant association with Wnt1 or
-catenin in NSCLC. This result suggested that GSK-3
might be regulated by another Wnt family member in lung
cancer. On the contrary, the overexpression of p53 was
significantly associated with GSK-3 expression as well as
smoking, SCC histology, and poor prognosis of the patients,
whereas it was not associated with the expression of Wnt1/
-catenin in this study.
A possible crosstalk between p53 and -catenin has
been suggested, in which elevated levels of p53 downregulate
-catenin through GSK-3 in variety of cell types, because
the ability of p53 to lower -catenin is blocked by the LiCl,
which inhibits the activity of GSK-3.10 However, the exact
molecular mechanism responsible for the p53 overexpression
associated with GSK-3 in this study remains to be eluci-
dated. Furthermore, we have been unable to demonstrate a
direct protein-protein interaction between p53 and -catenin,
TABLE 5. Multivariate Analysis Results of Overall Survival
Variables HR 95% CI p
p stage I 0.001
p stage II 1.757 0.735–4.198 0.205
p stage III 4.962 2.242–10.982 0.001
p stage IV 7.836 2.924–21.000 0.001
Pleural invasion 1.938 1.172–3.203 0.001
Lymphatic invasion 2.010 1.118–3.614 0.001
EOCG PS 3.510 2.125–5.797 0.001
Wnt1 1.699 1.039–2.778 0.035
-Catenin 2.165 1.092–4.293 0.027
p stage I 0.001
p stage II 1.838 0.772–4.378 0.169
p stage III 5.272 2.377–11.690 0.001
p stage IV 7.611 2.838–20.412 0.001
Pleural invasion 1.916 1.160–3.167 0.011
Lymphatic invasion 1.938 1.076–3.490 0.028
EOCG PS 3.472 2.109–5.715 0.001
Wnt1/-catenin 2.152 1.320–3.507 0.002
p stage I 0.001
p stage II 2.172 0.885–5.335 0.091
p stage III 9.814 4.670–20.625 0.001
p stage IV 9.907 3.660–26.815 0.001
Age 2.164 1.301–3.598 0.003
Gender 0.745 0.403–1.377 0.348
Histology 1.805 1.053–3.096 0.032
Wnt1/-catenin 2.371 1.421–3.959 0.001
p53 1.559 0.949–2.562 0.080
Variable 1, Wnt1 and -catenin were independent prognostic factors adjusted by p
stage, pleural invasion, lymphatic invasion, and EOCG PS.
Variable 2, Wnt1/-catenin expression was an independent factor adjusted by p
stage, pleural invasion, lymphatic invasion, and EOCG PS.
Variable 3, Wnt1/-catenin expression was an independent factor adjusted by p
stage, age, gender, histology, and p53.
HR, hazard ratio; CI, confidence interval; p stage, pathological stage; EOCG PS,
Eastern Cooperative Oncology Group performance status.
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suggesting that p53 may operate independently of other
aspects of Wnt signaling pathway dysregulation.
In summary, this study has shown that (1) aberrant
expression of Wnt1 and its downstream target molecule
-catenin are independent prognostic factors regardless of
TNM stage in NSCLC, (2) Wnt1 expression was significantly
associated with altered expression of -catenin and overex-
pression of c-Myc or cyclin D1, and (3) Wnt1 may be one of
the possible mechanisms of the activation of the canonical
Wnt/-catenin signaling pathway in lung cancer.
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